Yuna Rapoport, MD
Ophthalmology · New York, NYNPI 1144516121
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Sight Sciences, Inc. at 32.4% of the total. 2025 is the largest year on record at $36,967, more than ten times the $2,561 reported in 2019. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 346 payments — averaging $259.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$29K
- Tarsus Pharmaceuticals, Inc.$19K
- Carl Zeiss Meditec, Inc.$14K
- Bausch & Lomb Americas Inc.$12K
- Alcon Research LLC$3K
- Johnson & Johnson Surgical Vision, Inc.$2K
- plus $10K from 19 others
Across 5 payments — averaging $3000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tarsus Pharmaceuticals, Inc.$15K
What the payments were for
- Consulting fees$50,15056%
- Speaking & faculty fees$17,80320%
- Travel & lodging$7,9609%
- Food & beverage$12,60514%
- Education$1,4382%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 35 | $29,168 |
| Tarsus Pharmaceuticals, Inc. | 60 | $19,030 |
| Carl Zeiss Meditec, Inc. | 9 | $14,319 |
| Bausch & Lomb Americas Inc. | 24 | $12,210 |
| Alcon Research LLC | 1 | $3,000 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $2,061 |
| AbbVie(2 entities) | 13 | $1,761 |
| Oyster Point Pharma, Inc. | 51 | $1,645 |
| Sun Pharmaceutical Industries Inc. | 46 | $1,578 |
| Mallinckrodt Hospital Products Inc. | 41 | $1,098 |
| Tersera Therapeutics LLC | 1 | $950 |
| Harrow Eye, LLC | 14 | $639 |
| Dompe US, Inc. | 9 | $490 |
| Alcon | 9 | $478 |
| Pacira Pharmaceuticals Incorporated | 1 | $368 |
| Glaukos Corporation | 2 | $302 |
| Novartis | 7 | $218 |
| Haag-streit USA, Inc. | 1 | $168 |
| Aerie Pharmaceuticals, Inc. | 3 | $156 |
| Kala Pharmaceuticals, Inc. | 3 | $125 |
| Ocular Therapeutix, Inc. | 1 | $94 |
| Astellas Pharma US Inc | 1 | $28 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $27 |
| Eyevance Pharmaceuticals LLC | 1 | $22 |
| Amgen | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TearCare SmartLid$12,118
- TEARCARE(TM) (2.2) SYSTEM KIT$12,118
- MIEBO$11,358
- TEARCARE SYSTEM$11,299
- OMNI(R) SURGICAL SYSTEM (US)$5,342
- XDEMVY$4,650
- Tecnis 1-piece IOL$1,589
- Tecnis 3-piece IOL$1,589
- Tecnis Symphony IOL$1,589
- Tecnis Symphony Toric IOL$1,589
- XIIDRA$1,525
- VisuMax$1,485
- RESTASIS$1,250
- SION SURGICAL INSTRUMENT$750
- CEQUA$678
- TYRVAYA$504
- EXPAREL$368
- enVista MX60 IOL$368
- Clareon$319
- iStent inject Trabecular Micro-Bypass Stent System$161
How this compares
$89,955 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 91 | $65,453 |
| XdemvyLotilaner | 29 | $53,964 |
| XiidraLifitegrast | 18 | $14,425 |
| MieboPerfluorohexyloctane/Pf | 15 | $11,091 |
| Ofloxacin | 248 | $2,933 |
| Prednisolone Acetate | 71 | $2,530 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 14 | $538 |
| Latanoprost | 30 | $265 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 11 | $241 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 14 | $139 |
| Doxycycline Hyclate | 12 | $77 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $1,761 | $65,45391 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $19,030 | $53,96429 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $12,210 | $25,51633 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in New York
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
- Michael CooneyNew York$398K
- David GuyerNew York$322K
- Ashley BrissetteNew York$315K
- Jason SlakterNew York$272K
- David ChuNew York$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.